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Wang et al.1 report the joint effect of genetic variants in both the nuclear and 
mitochondrial DNA (mtDNA) on the occurrence of Kallman Syndrome in a large 
Han Chinese family. The nuclear variant (KAL1 c.146G>T, p.Cys49Phe) is not 
expected to cause changes to protein structure or function. Although the 
pathogenicity of the mitochondrial variant (tRNAcys, m.5800A>G) has been 
predicted2, there is no empirical evidence to support that prediction and it was 
not found to depress cellular oxidative phosphorylation1. Their interpretation is 
that the two point mutations act synergistically, causing abnormal migration of 
gonadotropin-releasing hormone neurons, which is thought to be the underlying 
mechanism for this developmental disorder. Since mutations in both genomes 
are required for manifestation of the phenotype, their results challenge how 
mitochondrial disease may be defined. We suggest that this two-locus/genome 
model of mitochondrial disease phenotypes may apply more broadly than is 
currently appreciated. Although the action of genetic background or modifiers 
have been implicated in altering the penetrance of primary pathological 
mutations underlying mitochondrial disease, reviews of this evidence have 
focused on specific disease sub-types3. Here, a review of the published evidence 
from the medical literature suggest that mitonuclear epistatic interactions are 
widespread and make a significant contribution to the variability in disease 
penetrance, which is a widely reported feature of mitochondrial pathologies4. We 
have identified 15 loci in mtDNA where the pathogenic effect (spanning a 
number of different mitochondrial diseases) is dependent upon the nuclear 
background, specific nuclear polymorphic sites, or expression levels of nuclear 
genes (Supplementary Table). In most cases, the defect in the mtDNA can be 
modified by multiple different nuclear loci, although some ‘master modifiers’ 
appear capable of influencing multiple mtDNA mutations (e.g. VARS2, LARS2). A 
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further 10 nuclear loci have been identified where mitochondrial haplotype (or 
variants) have modified the pathogenic phenotype, which includes type II 
diabetes and Alzheimer’s disease as well as classical mitochondrial diseases. 
Only 6 of these loci co-localize to mitochondria. In one example, the deleterious 
effect of the m.5703G>A mutation in human cell lines disappeared after a period 
of time in culture5. However, replacement of the nuclear background (using 
cybrids) reintroduced the deleterious phenotype. These data support a 
compensatory model of evolution within the nuclear genome in response to the 
presence of deleterious mutations within the mitochondrial genome. Together 
these studies highlight the potential role of mitonuclear epistasis in the 
expression and penetrance of human mitochondrial disease. This body of 
evidence also contradicts assertions made during the debate over the safety and 
efficacy of mitochondrial replacement therapies about the role of mitonuclear 
interactions on human phenotypes. It is clear from the evidence we review here 
that predicting the outcome of nuclear transfer into new mitochondrial 
backgrounds will be difficult6, and would require a more far more complete 
understanding of inter-genomic epistasis than we currently have.  
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